We could not find any results for:
Make sure your spelling is correct or try broadening your search.
WESTON, FL , DNAPrint Genomics, Inc. (OTCBB: DNAG), Paradigm Medical Industries, Inc. (OTCBB: PMED), Apple (NASDAQ: AAPL). Visit TheSUBWAY's Small Cap Investor Forum...
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company?) is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc...
NEW YORK, Sept. 7 /PRNewswire-FirstCall/ -- Richard Gabriel, Chief Executive Officer of DNAPrint Genomics, Inc. (OTC:DNAG) (BULLETIN BOARD: DNAG) (http://www.dnaprint.com/) will be featured in...
DNAPrint genomics Launches New Corporate Marketing and Product Branding Campaign Features Two Redesigned and Upgraded Web Sites SARASOTA, Fla., July 25 /PRNewswire-FirstCall/ -- DNAPrint...
DNAPrint genomics' Forensics Technology Featured in Presentation to Florida Sex Crimes Investigators Association SARASOTA, Fla., July 18 /PRNewswire-FirstCall/ -- DNAPrint genomics...
DNAPrint genomics Acquires 18% Stake in German Company Creates New Product Pipeline for Pharmaceutical Products SARASOTA, Fla., July 13 /PRNewswire-FirstCall/ -- DNAPrint genomics...
DNAPrint genomics Upgrades Genotyping Platform SARASOTA, Fla., July 12 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC:DNAG) (BULLETIN BOARD: DNAG) today announced an upgrade in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 100000 | 1.0E-6 | CS |
4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 128333 | 1.0E-6 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 65483 | 1.0E-6 | CS |
26 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 27495 | 1.09E-6 | CS |
52 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 96303 | 1.01E-6 | CS |
156 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 112476 | 1.08E-6 | CS |
260 | 0 | 0 | 1.0E-6 | 0.001 | 1.0E-6 | 741311 | 0.00035114 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions